Contesta las siguientes preguntas y mándanos tus respuestas para ganar un premio. En el suigiente volumen se dirán los primeros cinco ganadores.
1. ¿Cómo se caracteriza la etapa prodrómica y en qué momento de la enfermedad se presenta?
2. ¿Cuál es la relación entre el medio ambiente y el riesgo de padecer la enfermedad?
3. ¿Cuál es la terapia más prometedora para la enfermedad de Parkinson?
Preguntas de recapitulación
Referencias
1. Ahmed, H., Abushouk, A. I., Gabr, M., Negida, A., & Abdel-Daim, M. M. (2017). Parkinson’s disease and pesticides: A meta-analysis of disease connection and genetic alterations. Biomedicine & Pharmacotherapy, 90, 638-649.
2. AlDakheel, A., Kalia, L. V., & Lang, A. E. (2014). Pathogenesis-Targeted, Disease-Modifying Therapies in Parkinson Disease. Neurotherapeutics, 11(1), 6–23. http://doi.org/10.1007/s13311-013-0218-1
3. Baradaran, N., Tan, S. N., Liu, A., Ashoori, A., Palmer, S. J., Wang, Z. J., … McKeown, M. J. (2013). Parkinson’s Disease Rigidity: Relation to Brain Connectivity and Motor Performance. Frontiers in Neurology, 4, 67. http://doi.org/10.3389/fneur.2013.00067
4. Barker, R. A., Parmar, M., Studer, L., & Takahashi, J. (2017). Human Trials of Stem Cell-Derived Dopamine Neurons for Parkinson’s Disease: Dawn of a New Era. Cell Stem Cell, 21(5), 569-573.
5. Bega, D., & Zadikoff, C. (2014). Complementary & Alternative Management of Parkinson’s Disease: An Evidence-Based Review of Eastern Influenced Practices. Journal of Movement Disorders, 7(2), 57–66. http://doi.org/10.14802/jmd.14009
6. Blesa, J., Trigo-Damas, I., Quiroga-Varela, A., & Jackson-Lewis, V. R. (2015). Oxidative stress and Parkinson’s disease. Frontiers in Neuroanatomy, 9, 91. http://doi.org/10.3389/fnana.2015.00091
7. Bohnen, N. I., & Albin, R. L. (2011). The Cholinergic System and Parkinson Disease. Behavioural Brain Research, 221(2), 564–573. http://doi.org/10.1016/j.bbr.2009.12.048
8. Bradicinesia. (2017). Etimologias.dechile.net. Recuperado 10 noviembre 2017 de http://etimologias.dechile.net/?bradicinesia
9. Brigo, F., Erro, R., Marangi, A., Bhatia, K., & Tinazzi, M. (2014). Differentiating drug-induced parkinsonism from Parkinson's disease: an update on non-motor symptoms and investigations. Parkinsonism & related disorders, 20(8), 808-814.
10. Brooks, D. J. (2008). Optimizing levodopa therapy for Parkinson’s disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective. Neuropsychiatric Disease and Treatment, 4(1), 39–47.
11. Brooks, D. J., & Pavese, N. (2011). Imaging biomarkers in Parkinson's disease. Progress in neurobiology, 95(4), 614-628.
12. Brüggemann N, Klein C. Parkin Type of Early-Onset Parkinson Disease. 2001. [Revisado 4 de abril de 2013]. En: Adam MP, Ardinger HH, Pagon RA, et al. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2017. Recuperado de https://www.ncbi.nlm.nih.gov/books/NBK1478/
13. Chen, P. H., Wang, R. L., Liou, D. J., & Shaw, J. S. (2013). Gait disorders in Parkinson's disease: assessment and management. International Journal of Gerontology, 7(4), 189-193.
14. Chen, W., Hopfner, F., Becktepe, J. S., & Deuschl, G. (2017). Rest tremor revisited: Parkinson’s disease and other disorders. Translational Neurodegeneration, 6, 16. http://doi.org/10.1186/s40035-017-0086-4
15. Cheng, H.-C., Ulane, C. M., & Burke, R. E. (2010). Clinical Progression in Parkinson’s Disease and the Neurobiology of Axons. Annals of Neurology, 67(6), 715–725. http://doi.org/10.1002/ana.21995
10